We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Voyager Therapeutics

News List

Following deal focused on Alzheimer's disease, AbbVie, Voyager Therapeutics expand collaboration to Parkinson's disease firstwordpharma
February 23, 2019
AbbVie entered an exclusive global agreement with Voyager Therapeutics to develop vectorised antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson's disease and other diseases characterised by the abnormal
Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech roles pharmaphorum
January 17, 2019
Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZeneca.
Voyager Therapeutic's Parkinson's Trial Shows Positive Results biospace
March 12, 2018
Voyager Therapeutics, headquartered in Cambridge, Massachusetts, released longer-term data from its ongoing Phase Ib clinical trial of VY-AADC in advanced Parkinson’s disease.